NorthStar Medical Radioisotopes and BWXT Medical, a subsidiary of BWX Technologies, have signed a master services agreement for the production of actinium-225 (Ac-225), an isotope used in cancer diagnostics and therapy.
Through the multiyear agreement, the companies will work together to process and purify radium-226, which decays to Ac-225. The scope of the agreement also includes potential target design projects and exploration of opportunities to provide backup supply to each other’s customers, according to the firms.
BWXT Medical said it will collaborate with NorthStar to streamline production processes, enhance safety protocols, and develop new methods of isotope generation. The firm recently submitted a drug master file for Ac-225 API to the U.S. Food and Drug Administration (FDA), which enables clinical investigators or pharmaceutical companies to reference the filing in their regulatory submissions.
